Company / Cash & Equivalents
Voyager Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$65.3M
FY2025
5-year range
$65.3M / $117.4M
FY2021-FY2025
Trend
-8.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $7M in FY2016 to $117M in FY2022.
Based on SEC 10-K filings.
$65M in FY2025 with a 5-year CAGR of -5.4%.
Declined from $69M to $65M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.8%
- 5-Year CAGR
- -5.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -5.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 8.5% year-over-year.
- Peak cash & equivalents was recorded in FY2022.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $65.3M | -8.5% |
| FY2024 | $71.4M | +3.7% |
| FY2023 | $68.8M | -41.4% |
| FY2022 | $117.4M | +12.4% |
| FY2021 | $104.4M | +21.4% |
| FY2020 | $86.0M | +83.6% |
| FY2019 | $46.9M | +48.6% |
| FY2018 | $31.5M | -13.9% |
| FY2017 | $36.6M | +420.8% |
| FY2016 | $7.0M | +5111.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026